jueves, 8 de marzo de 2018

What's New in Regulatory Science


The State of CDER 2018 podcast
Dr. Woodcock reflects on the accomplishments and highlights of 2017, and previews what is planned for 2018 in such areas as patient-focused drug development, drug compounding, modernizing FDA’s IT platform, and addressing the opioid crisis.

Click here to download the podcast and to obtain transcript information.

The Role of Consortia in Biomarker Development and Qualification

The FDA’s Biomarker Qualification Program Educational Module Series describes CDER’s scientific public-private partnerships (consortia), how CDER engages with them, and how they can advance biomarker development. Click here to view the module.

No hay comentarios: